Clinical Trial Update: Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions [Phase 2]

View source ↗

Summary

Phase 2 study assessing repeat dosing of Mizagliflozin and its impact on adverse events and postprandial glucose excursions in individuals with postbariatric hy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postbariatric Hypoglycemia

Drugs mentioned

• Mizagliflozin (Mizagliflozin)

Snippet

Sponsor: Vogenx, Inc. | Conditions: Postbariatric Hypoglycemia | Phase 2 | Status: COMPLETED